



Mucosal Fungal Infections

Guest Editors:

Prof. Julian Naglik

Mucosal and Salivary Biology
Division, King's College London
Dental Institute, King's College
London, London, United
Kingdom

julian.naglik@kcl.ac.uk

Dr. Jonathan Richardson

Mucosal and Salivary Biology
Division, King's College London
Dental Institute, King's College
London, London, United
Kingdom

jonathan.richardson@kcl.ac.uk

Deadline for manuscript
submissions:

closed (30 September 2017)

Message from the Guest Editors

Dear Colleagues,

The impact of mucosal-acquired fungal infections on healthcare is large and of growing concern. *Candida*, *Aspergillus*, and *Cryptococcus* species are common fungal pathogens that cause life-threatening infections in millions of immunocompromised individuals worldwide each year. The incidence of systemic fungal infections is rising and can be considered more deadly than most bacterial infections, including all Gram-negative septicaemias. The alarmingly high mortality rate for systemic fungal infections is due to ineffective outcomes associated with current antifungal therapies, a lack of accurate diagnostic tests for the early detection of potentially fatal infections, and no available fungal vaccine. This Special Issue will collate the recent advances in our understanding of fungal–epithelial interactions and immunity against these mucosal-acquired fungal infections.

Prof. Julian Naglik

Dr. Jonathan Richardson

Guest Editors

- Mucosal
- Epithelial
- Immunity
- Innate
- Adaptive
- *Candida*

<





Editor-in-Chief

Prof. Dr. David S. Perlin

Hackensack Meridian Health
Center for Discovery and
Innovation, 340 Kingsland Street,
Nutley, NJ 07110, USA

Message from the Editor-in-Chief

The *Journal of Fungi* (JoF, ISSN 2309-608X) is an international, peer-reviewed, scientific, open access journal that provides an advanced forum for studies related to pathogenic fungi, fungal biology, and all other aspects of fungal research. Research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. The publication fees are fully waived for papers submitted in 2018. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: Indexed in the Science Citation Index Expanded (SCIE - Web of Science), BIOSIS Previews, Chemical Abstracts / SciFinder (ACS), as well as *Scopus*. Citations available in *PubMed*, full-text archived in PubMed Central.

Rapid Publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 17.3 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2019).

Contact Us